LudaCure Co., Ltd. (CEO Yongho Kim) was selected as an excellent company (promising company) in Incheon City at the '2025 Incheon Small and Medium Business Awards and Excellent Company Certificate Ceremony' hosted by Incheon Metropolitan City and organized by Incheon Techno Park on November 12.
Founded in 2018, LudaCure focuses on developing treatments for sensory disorders such as dry eye and chronic pain based on a novel drug platform that directly and indirectly modulates the TRPV1 (Transient Receptor Potential Vanilloid 1) ion channel. Its flagship pipeline, RCI001, targets dry eye and suppresses inflammatory activation by modulating TRPV1 downstream signaling, demonstrating potent anti-inflammatory and antioxidant effects.
LudaCure signed a technology transfer contract worth a total of 20 billion won with Hanlim Pharmaceutical in 2021 and 2022, and secured an IND for phase 2 clinical trials from the US FDA in July 2025. It is also expanding its business area into the animal pharmaceutical market through a 50 billion won contract with a French global animal pharmaceutical developer. RCI002, a chronic pain treatment, is a non-opioid analgesic that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor). In non-clinical trials, it confirmed the characteristics of long-lasting effects and no side effects at low concentrations compared to existing treatments.
CEO Yong-ho Kim said, “This selection as an excellent company in Incheon is the result of external recognition of our R&D capabilities and innovative technologies,” and added, “Based on our TRPV1 modulation platform, we will provide safe and effective treatment options for patients with sensory disorders and grow into a new drug development company with competitiveness in the global market.”
You must be logged in to post a comment.